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Abstract
Introduction: Lipodystrophies are a heterogeneous group of 
rare diseases (genetic or acquired) characterized by a partial 
or generalized deficit of adipose tissue, resulting in less en-
ergy storage capacity. They are associated with severe endo-
crine-metabolic complications with significant morbidity 
and mortality. In the pathogenesis of the acquired forms, im-
munological disorders may be involved. Case 1: A 13-year-
old female was diagnosed with acquired generalized lipodys-
trophy and observed for suspicion of portal hypertension. 
She presented with generalized absence of adipose tissue, 
cervical and axillary acanthosis nigricans, and massive hepa-
tosplenomegaly. Laboratory tests revealed AST 116 IU/L, ALT 
238 IU/L, GGT 114 IU/L, HOMA-IR 28.2, triglycerides 491 mg/L, 
and leptin < 0.05 ng/mL. Upper gastrointestinal endoscopy 
saw no signs of portal hypertension. Hepatic histology 
showed macrovesicular fatty infiltration (60% of hepato-
cytes) and advanced fibrosis/cirrhosis. Her clinical condition 
worsened progressively to diabetes requiring treatment with 
subcutaneous insulin and hepatopulmonary syndrome. Case 
2: A 15-year-old female, diagnosed with acquired partial lipo-
dystrophy, Parkinson syndrome, autoimmune thyroiditis, 
and autoimmune thrombocytopenia was observed for hy-
pertransaminasemia since the age of 8 years. She had ab-
sence of subcutaneous adipose tissue in the upper and lower 
limbs and ataxia. Laboratory tests showed AST 461 IU/L, ALT 
921 IU/L, GGT 145 IU/L, HOMA-IR 32.6, triglycerides 298 mg/
dL, normal leptin levels, platelets 84,000/μL, IgG 1,894 mg/dL, 
positive anti-LKM and anti-LC-1. Hepatic histology was sug-
gestive of autoimmune hepatitis, without steatosis. She pro-
gressed favorably under metformin and immunosuppressive 
treatment. Conclusion: Early recognition and adequate char-
acterization of liver disease in lipodystrophies is essential for 
a correct treatment approach. In acquired generalized lipo-
dystrophy, the severe endocrine-metabolic disorder, which 
leads to steatohepatitis with cirrhotic progression, may ben-
efit from recombinant leptin treatment.
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Fígado gordo e hepatite autoimune: duas formas de 
atingimento hepático nas lipodistrofias
Palavras Chave
Lipodistrofia · Lipodistrofia generalizada adquirida · 
Lipodistrofia parcial adquirida · Fígado gordo · Hepatite 
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Resumo
Introdução: As lipodistrofias são um grupo heterogéneo 
de doenças raras (formas genéticas e adquiridas) caracter-
izadas por défice parcial ou generalizado de tecido adi-
poso, resultando em menor capacidade de armaze-
namento energético. Estão associadas a complicações 
endócrino-metabólicas graves com morbilidade e mor-
talidade significativas. Na patogénese das formas adqui-
ridas poderão estar envolvidos distúrbios imunológicos. 
Caso 1: Adolescente de 13 anos, sexo feminino, com di-
agnóstico de lipodistrofia generalizada adquirida, obser-
vada por suspeita de hipertensão portal. Apresentava 
ausência generalizada de tecido adiposo, acantose nigri-
cans cervical e axilar, e hepatoesplenomegalia volumosa. 
Do estudo destacavam-se: AST 116 UI/L, ALT 238 UI/L, 
GGT 114 UI/L, HOMA-IR 28.2, triglicerídeos 491 mg/L e 
leptina < 0.05 ng/mL. A endoscopia digestiva alta não ev-
idenciou sinais de hipertensão portal. Histologia hepática 
com esteatose macrovesicular (60% dos hepatócitos) e fi-
brose avançada/cirrose. A sua condição clínica evoluiu 
progressivamente para diabetes com necessidade de 
tratamento com insulina subcutânea e síndrome hepato-
pulmonar. Caso 2: Adolescente de 15 anos, sexo femini-
no, com diagnóstico de lipodistrofia parcial adquirida, sín-
drome parkinsónico, tiroidite autoimune, e tromboci-
topenia autoimune, observada por elevação das 
transaminases desde os 8 anos. Apresentava ausência de 
tecido adiposo subcutâneo nos membros superiores e in-
feriores, ataxia e tremor das mãos, sem sinais de doença 
hepática. Do estudo destacavam-se: AST 461 UI/L, ALT 
921 UI/L, GGT 145 UI/L, HOMA-IR 32,6, triglicerídeos 298 
mg/dL, leptina normal, plaquetas 84,000/μL, IgG 1,894 
mg/dL, anticorpos anti-LKM e anti-LC1 positivos. Histolo-
gia hepática sugestiva de hepatite autoimune, sem estea-
tose. A doente evoluiu favoravelmente com metformina 
e tratamento imunossupressor. Discussão: O reconheci-
mento precoce e a caracterização adequada da doença 
hepática nas lipodistrofias são fundamentais para uma 
correta abordagem terapêutica. Na lipodistrofia general-
izada adquirida, o distúrbio endócrino-metabólico grave 
responsável por esteatohepatite com evolução cirrogé-
nea poderá beneficiar do tratamento inovador com lepti-
na recombinante. © 2019 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Lipodystrophies are a heterogeneous group of rare 
diseases characterized by partial or complete absence of 
adipose tissue resulting in the reduction of energy stor-
age capacity with no nutritional deprivation or catabolic 
state [1]. According to its etiology (genetic or acquired) 
and the distribution of lost adipose tissue (partial or gen-
eralized), they can be categorized into four main catego-
ries: congenital generalized lipodystrophy, acquired 
generalized lipodystrophy (AGL), familial partial lipo-
dystrophy, and acquired partial lipodystrophy (APL) 
[1, 2].
Lipodystrophies are considered ultra-rare diseases 
with an estimated prevalence of 1.3–4.7 cases/million, 
which explains the low awareness of the majority of clini-
cians for their diagnosis and management [3, 4]. These 
diseases have a significant impact on the patient’s life due 
to endocrine-metabolic morbidity and a psychological 
impact on body image [1, 5].
Their main features are deficiency in/resistance to 
leptin because of adipose tissue loss, leading to severe 
complications such as immunological impairment, hor-
mone dysfunction, and glucose and fat metabolism im-
pairment with ectopic fat accumulation, leading to organ 
disfunction (mainly liver, kidney, and heart) and prema-
ture deaths [6].
The type of liver disease in lipodystrophies is related to 
their pathophysiology or possible underlying pathogen-
esis. The authors present two patients with lipodystrophy 
illustrating both situations.
Case Report
Case 1
A 12-year-old girl was first seen at the Pediatric Hepatology 
outpatient clinic for voluminous hepatosplenomegaly and suspi-
cion of portal hypertension. Her family history was unremarkable. 
The girl had been diagnosed with generalized lipodystrophy at 
the age of 4 (when changes in body composition were noted) and, 
at the age of 8 years, she developed physical signs of insulin resis-
tance (acanthosis nigricans). By the age of 10, echocardiography 
assessment revealed a concentric left ventricular hypertrophy, rec-
ommending avoidance of sports. Laboratory tests showed neutro-
penia and iron deficiency anemia that resolved with oral iron treat-
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ment. Despite extensive workup, neutropenia of unknown etiol-
ogy persisted. At the age of 11, she had hepatosplenomegaly and 
the possibility of portal hypertension was considered. 
Physical examination revealed generalized loss of adipose tis-
sue with hand and foot involvement (Fig. 1a), cervical, axillary and 
inguinal acanthosis nigricans (Fig. 1b), and massive hepatomegaly 
and splenomegaly (Fig. 1c).
Abdominal ultrasound with Doppler showed an enlarged liver 
(240 mm) being diffusely hyperechogenic and homogeneous, in-
creased flow velocity of the portal vein (33.1 cm/s), elevation of the 
hepatic artery Doppler resistance index (0.75), decreased respira-
tory variation in supra-hepatic veins, and an enlarged spleen (160 
mm) with a homogeneous echo pattern. Upper gastrointestinal 
endoscopy was normal. Liver histology revealed architectural dis-
tortion, portal fibrosis with septa, bridges and parenchymal nodu-
larity, macrovesicular hepatocellular steatosis (60% of hepato-
cytes), ballooning degeneration of hepatocytes, and inflammatory 
infiltrate composed of lymphocytes (Fig.  2a, b). These findings 
a
b
c
Fig. 1. a Generalized loss of adipose tissue. 
b Prominent axillar acanthosis nigricans. 
c Voluminous hepatosplenomegaly.
a 200 µm 100 µmb
Fig. 2. a, b Macrovacuolar steatosis, inflammation and fibrosis (H&E).
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were consistent with nonalcoholic steatohepatitis diagnosis with 
advanced fibrosis and progression to cirrhosis.
Laboratory tests revealed an undetectable serum leptin level 
(< 0.05 ng/mL) with a normal immunological study. Molecular 
study for genetic lipodystrophies (AGPAT2, BSCL2, PPARG and 
LMNA genes) was negative and she was classified as AGL.
Regarding the evolution of biochemical parameters (Table 1), 
by 7 years of age, the patient already evidenced raised transami-
nases and gamma-glutamyl transferase (GGT), increased HOMA-
IR, and hypertriglyceridemia. At 10 years of age, she started treat-
ment with metformin (500 mg b.i.d.) and enalapril (10 mg/day) 
because of arising microalbuminuria. There was a transient im-
provement of her metabolic syndrome, which, however, worsened 
by the age of 12. Metformin treatment was optimized (1 g b.i.d.) 
and losartan (50 mg/day) was added due to microalbuminuria ex-
acerbation. Ursodeoxycholic acid (500 mg b.i.d.) and gemfibrozil 
(600 mg/day) were added, with no significant improvement. Re-
cently, she has been treated with subcutaneous insulin.
Currently, at the age of 13, clinical and biochemical deterioration 
is evident, with severe hypertransaminasemia, insulin resistance, hy-
pertriglyceridemia, and microalbuminuria. We applied her to the 
program of early access to treatment with recombinant human leptin, 
which has recently been authorized. In the last assessment, she had a 
transcutaneous oximetry of 96%; lung scintigraphy revealed 12% of 
radiopharmaceutical activity outside the lungs, showing a small right-
left shunt, consistent with hepatopulmonary syndrome settlement. 
Case 2
A 15-year-old girl was admitted to the Pediatric Hepatology 
outpatient clinic for elevated transaminases since the age of 8. Her 
family history revealed a 40-year-old mother with liver steatosis 
and a 41-year-old father with hypercholesterolemia and type 2 di-
abetes mellitus.
The patient had had neurological impairment since birth with 
global developmental delay, nonprogressive congenital ataxia, and 
oculomotor disturbances. By the age of 7, the first signs of a progres-
sive kyphoscoliosis were noted, and, in the second decade of her life, 
her neurological condition evolved to a parkinsonian syndrome. 
Brain magnetic resonance imaging showed iron accumulation in the 
substantia nigra and globus pallidus (Fig. 3, arrow), consistent with 
neurodegeneration with brain iron accumulation diagnosis. 
By the age of 3, she started losing adipose tissue in limb ex-
tremities and magnetic resonance imaging of the limbs supported 
the diagnosis of partial lipodystrophy. Molecular study of the 
AGPAT2 gene was normal. At the age of 14, autoimmune thyroid-
itis and thrombocytopenia were diagnosed. Raised transaminases 
were noted since the age of 8, with an asymptomatic raise to 10 
times the upper limit of the normal range some weeks before ad-
mission to Hepatology consultation, at 15 years old. 
Physical examination enhanced symmetrical distal absence of 
subcutaneous adipose tissue in upper and lower limbs, central obe-
sity, kyphoscoliosis, ataxic gait, and upper limb tremor (Fig. 4, 5). 
There were no signs of chronic liver disease.
Laboratory tests evidenced elevated AST (461 IU/L), ALT (921 
IU/L), GGT (93 IU/L), triglycerides (339 mg/dL), thrombocytope-
nia (63,000/μL), elevated IgG level (1,894 mg/dL), partial IgA de-
ficiency (9.6 mg/dL), positive anti-LKM1 (1/640), and anti-LC1 
antibodies. Leptin serum levels were normal. Abdominal ultra-
sound showed a liver with normal echogenicity and dimensions 
and a discrete homogeneous splenomegaly. Liver histology re-
vealed a portal fibrous mass with partial nodular transformation, 
Fig. 3. Iron accumulation in the substantia 
nigra and globus pallidus (arrow). 
Table 1. Evolution of biochemical parameters of case 1
Age, years and months 7y6m 10y1m 11y0m 12y0m 12y11m 13y3m 13y9m
AST (nr <30), IU/L 97 227 116 116 203 126 235
ALT (nr <36), IU/L 291 479 238 177 250 283 310
GGT (nr <39), IU/L 97 138 114 171 239 164 225
HOMA-IR (nr <3.4) 7.4 54.3 28.2 75.9 38.2 68.7 28.5
HbA1c (nr <5.7%) 5.2 5.5 5.8 6.5 6.5 5.3 7.3
Microalbuminuria (nr <12.3), mg/g 5.7 21.5 60.9 60.0 333.2 594.2 730.0
Total cholesterol (nr <205), mg/dL 151 162 195 263 190 214 190
LDL-cholesterol (nr <136), mg/dL 65 66 98 129 74 47 62
Triglycerydes (nr <120), mg/dL 327 367 491 1,479 805 1,280 896
AST, aspartate transaminase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HOMA-IR, homeostatic model 
assessment for insulin resistance; HbA1c, glycated hemoglobin A1c; LDL, low-density lipoprotein; nr, normal range.
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dense inflammatory infiltrate composed of lymphocytes and plas-
ma cells, which crosses the limiting plate and invades the sur-
rounding parenchyma (interface hepatitis). These findings were 
compatible with autoimmune hepatitis diagnosis (Fig. 6a, b), with 
a pretreatment score of 20 points [7].
The patient was treated with prednisolone (1 mg/kg/day) as-
sociated 4 weeks later with azathioprine (1.5 mg/kg/day), allowing 
progressive withdrawal of steroids. Complete normalization of 
transaminases, GGT, IgG levels, and platelet count were achieved 
within 2 months. Insulin resistance (HOMA-IR = 32.5) was noted 
and improved significantly under metformin therapy (500 mg 
b.i.d.). Currently, at the age of 16 years, she remains under treat-
ment with azathioprine and prednisolone (5 mg/day), with no 
signs of recurrence of hepatitis, and she was classified as APL.
a
b
Fig. 4. a Central obesity. b Loss of adipose tissue at upper and lower extremities.
a bFig. 5. a Loss of adipose tissue in the hand. 
b Loss of adipose tissue in the foot.
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Discussion
The diagnosis of lipodystrophies relies on clinical his-
tory, physical examination, body composition, and meta-
bolic status [1]. Clinical phenotype and immunological/
autoimmune abnormalities are important tools to distin-
guish genetic from acquired lipodystrophies [8]. Genetic 
testing can be helpful in the suspicion of familial lipodys-
trophies and should be performed in the presence of a 
suggestive family history [1].
In case 1, lipodystrophy is generalized with predomi-
nant metabolic complications, such as insulin resistance, 
hypercholesterolemia, hypertriglyceridemia, ectopic fat 
accumulation manifested as a concentric left ventricular 
hypertrophy, and steatohepatitis that is progressing to 
cirrhosis. Since her family history and molecular study 
for congenital generalized lipodystrophy were negative, 
we assumed the diagnosis of AGL. 
In case 2, despite the absence of an exhaustive genetic 
study, the lack of a family history and its association with 
autoimmune disorders (hepatitis, thyroiditis, and throm-
bocytopenia) favor the presumptive diagnosis of an ac-
quired lipodystrophy. In this case, lipodystrophy is partial 
which can be easily misdiagnosed as common central 
obesity with metabolic syndrome. Liver involvement 
should have been suspected earlier, since the presence of 
hypertransaminasemia had been seen in a workup at the 
age of 8 years and not valorized and taken as incipient 
liver disease. Several neuromuscular abnormalities are 
described in lipodystrophies, particularly related to 
LMNA and BSCL2 gene mutation (genetic lipodystro-
phies) [9]. Neurodegeneration with brain iron accumula-
tion, observed in this patient, is a neurologic disorder 
characterized by abnormal accumulation of iron in basal 
ganglia resulting in progressive dystonia, parkinsonism, 
and neuropsychiatric abnormalities [10]. Currently, there 
is no association described between this entity and lipo-
dystrophy. Nevertheless, some studies suggest a relation-
ship between serum leptin levels and Parkinson’s disease 
[11].
The pathogenesis of fat loss in AGL remains unknown, 
despite several studies showing that 25% of cases are trig-
gered by localized panniculitis with generalized progres-
sion, 25% have concomitant autoimmune disorders, and 
the remainder have idiopathic etiology [6, 8]. However, 
AGL is often associated with autoimmune diseases that 
are not the rule, as seen in case 1 [1, 8, 12]. APL pathogen-
esis is also unknown. As proposed for AGL, autoimmune 
theories have been proposed as an etiological cause for 
adipose tissue destruction due to its connection with au-
toimmune diseases, such as membranoproliferative glo-
merulonephritis, dermatomyositis, systemic lupus ery-
thematosus, and autoimmune hepatitis [6, 8, 13]. Patient 
2 has a clear autoimmunity reactivity.
Adipose tissue is a well-recognized active endocrine 
metabolic system [6]. Leptin is the leading key adipokine 
in metabolic homeostasis and neuroendocrine modula-
tion with several functions, such as regulation of food in-
take, regulation of fatty acid metabolism, decrease in glu-
cose synthesis, and increase in glucose uptake in muscle, 
a 200 µm b 100 µm
Fig. 6. a, b Portal lymphoplasmacytic infiltrate (H&E).
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lipid uptake in adipocytes, regulation of gonadal steroids 
secretion, and modulation of immune response [14–16]. 
Adipocytes provide a benign place to store lipids, protect-
ing the organism from lipotoxicity [6]. Therefore, adipose 
tissue loss and resulting leptin deficiency can lead to seri-
ous clinical consequences developing at an early age, such 
as insulin resistance, impaired lipid storage with hyper-
triglyceridemia and fat ectopic accumulation in nonadi-
pose tissue and impaired immune response with suscep-
tibility for infection [8, 13].
Lipodystrophies are a secondary cause of fatty liver 
and by consequence one of the differential diagnosis of 
nonalcoholic fatty liver disease. Reduction of subcutane-
ous adipose tissue combined with leptin deficiency/resis-
tance transforms the liver into the main organ of triglyc-
erides accumulation [17]. Steatosis probably sensitizes 
the liver to metabolic injury leading to inflammation, ne-
crosis, and culminating in fibrosis, as seen in the first case 
[17, 18]. Liver failure and hepatocellular carcinoma can 
also result from steatohepatitis progression; consequent-
ly, liver disease is an important cause of death in these 
patients. Histological assessment is imperative, allowing 
evaluation of steatohepatitis severity and the presence of 
autoimmune features, which can concomitantly be pres-
ent in acquired lipodystrophies [6, 17]. Serum leptin lev-
els are directly proportional to adipocytes tissue mass and 
are typically low in patients with generalized lipodystro-
phy (as seen in case 1), with variable values found in par-
tial lipodystrophy [8, 19]. The severity of metabolic phe-
notype tends to be proportional to the grade of adipose 
tissue loss and, consequently, is tendentially worse in gen-
eralized lipodystrophy [20]. Metabolic complications are 
uncommon in APL, which is consistent with the less 
severe loss of adipose tissue and leptin levels [1, 6]. This 
was seen in case 2 in which the patient had a slight hyper-
triglyceridemia and insulin resistance compared with 
case 1. 
Lipodystrophies have no cure and currently available 
therapies are used with the main goal of preventing or 
ameliorating associated comorbidities, such as metabolic 
disturbance [1, 8]. Energy-restricted diets have shown to 
improve metabolic complications but have to be imple-
mented with caution in pediatric patients to avoid unbal-
anced requirements for an healthy development [1, 8]. In 
case 1, despite assertive pharmacological and nutritional 
management of metabolic complications, progressive 
worsening was observed with recent installation of hepa-
topulmonary syndrome. Physical activity was not an op-
tion due to arising cardiomyopathy. This is the natural 
history of generalized lipodystrophy, which is refractory 
to aggressive conventional therapy, as the main issue is 
the absence of leptin and its metabolic consequence [21]. 
In generalized lipodystrophies with severe leptin defi-
ciency, the endocrine-metabolic disorder responsible for 
steatohepatitis with cirrhotic evolution may benefit from 
human recombinant leptin (metreleptin – Myalepta®, 
Aegerion Pharmaceuticals) treatment, as shown by sev-
eral studies [8, 21]. Metreleptin has demonstrated to im-
prove metabolic abnormalities with significant reduction 
in steatohepatitis activity scores, steatosis, serum triglyc-
erides, transaminases, proteinuria, fasting glucose values, 
and hemoglobin A1c [17, 21]. Metreleptin is the only drug 
approved specifically for lipodystrophies and has recent-
ly been approved in the European Union as first-line ther-
apy for endocrine-metabolic abnormalities treatment of 
generalized lipodystrophy as well as for hypoleptinemic 
partial lipodystrophy [1, 8, 22]. In case 2, leptin serum 
levels were normal, and no benefit would be expected 
from metreleptin treatment. Liver disease, in this case, 
was not fatty liver, but instead, an autoimmune hepatitis. 
Treatment was applied according to guidelines, so far 
with full success [23].
In conclusion, accurate diagnosis and effective man-
agement of lipodystrophy comorbidities are imperative 
to improve patient outcome, namely early recognition 
and adequate characterization of liver disease. Liver func-
tion monitoring and the performance of a timely liver 
biopsy is recommended.
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